This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Total Brain Valuation

Is TTB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TTB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TTB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TTB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TTB?

Key metric: As TTB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TTB. This is calculated by dividing TTB's market cap by their current revenue.
What is TTB's PS Ratio?
PS Ratio	0.03x
Sales	AU$8.42m
Market Cap	AU$267.44k

TTB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.09x
Enterprise Value/EBITDA	-0.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does TTB's PS Ratio compare to its peers?

The above table shows the PS ratio for TTB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	12.6x
IIQ INOVIQ	31.4x	70.9%	AU$49.1m
AHX Apiam Animal Health	0.4x	n/a	AU$84.0m
RHY Rhythm Biosciences	16.9x	n/a	AU$28.6m
SLA SILK Laser Australia	1.8x	9.1%	AU$177.4m
TTB Total Brain	0.03x	n/a	AU$267.4k

Price-To-Sales vs Peers: TTB is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (6.6x).

Price to Sales Ratio vs Industry

How does TTB's PS Ratio compare vs other companies in the AU Healthcare Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	1.4x	6.9%
TTB Total Brain	0.03x	n/a	US$179.68k
FCG Freedom Care Group Holdings	0.1x	n/a	US$2.59m
HHI Health House International	0.05x	n/a	US$590.30k

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap
Industry Avg.	1.4x	26.3%
TTB Total Brain	0.03x	n/a	US$179.68k

No more companies

Price-To-Sales vs Industry: TTB is good value based on its Price-To-Sales Ratio (0x) compared to the Australian Healthcare industry average (1.1x)

Price to Sales Ratio vs Fair Ratio

What is TTB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TTB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.03x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TTB's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$127.8m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.08

5.9%

28.7%

Healius

AU$969.4m

Provides specialty diagnostic services to consumer and practitioners in Australia.

HLS

AU$1.33

-16.1%

-27.9%

Cogstate

AU$170.9m

A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.

CGS

AU$0.98

2.1%

-32.5%